Jinxin Fertility Group Limited (JXR) disclosed that it repurchased 1.36 million ordinary shares on 4 September 2026 through on-market transactions at prices ranging between HK$2.16 and HK$2.22, averaging HK$2.21 per share. The aggregate consideration amounted to HK$3.00 million.

Post-transaction, the company’s issued share capital excluding treasury shares fell by 0.05 % to 2.69 billion. Treasury share holdings increased to 12.13 million, while the total issued share count remained unchanged at 2.71 billion.

Under the general mandate approved on 25 June 2026, JXR is authorised to repurchase up to 262.51 million shares. Cumulative buybacks under this mandate now stand at 24.67 million shares, equivalent to 0.94 % of the share base when the mandate was granted, leaving roughly 237.84 million shares of remaining capacity.

Separately, 92.47 million shares repurchased between late March and August 2026 are earmarked for cancellation but had not yet been cancelled as of 4 September 2026. Pursuant to listing rules, JXR is subject to a moratorium on new share issues or treasury share disposals until 4 October 2026.